Chandra Bhagat Pharma Limited has informed BSE that corporate governance provisions under SEBI regulations are not applicable to the company for the quarter ended December 31, 2025. The filing was made on January 21, 2026, under Regulation 15 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Exemption Details

The company cited its listing on the SME Exchange as the basis for exemption from corporate governance requirements. Under SEBI Regulation 15, entities listed on SME exchanges are exempt from compliance with specific corporate governance provisions.

Corporate Governance Provisions Not Applicable

The exemption covers multiple regulations under SEBI (LODR) Regulations, 2015. Chandra Bhagat Pharma Limited is not required to comply with Regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, and 27. Additionally, the company is exempt from clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46, along with paragraphs C, D, and E of Schedule V.

SME Exchange Benefits

SEBI provides two categories of exemptions from corporate governance requirements:

• Listed entities with paid-up equity share capital not exceeding ₹10.00 crore and net worth not exceeding ₹25.00 crore as on the last day of the previous financial year
• Listed entities with specified securities listed on SME exchanges

Chandra Bhagat Pharma Limited falls under the second category due to its SME Exchange listing. This exemption eliminates the requirement to submit Corporate Governance Reports for the specified quarter.

Filing Authority

The certificate was signed by Rajni Dawani, Company Secretary and Compliance Officer of Chandra Bhagat Pharma Limited. The communication was addressed to the Manager – Listing Compliance, Department of Corporate Service at BSE Limited, Mumbai.

Chandra Bhagat Pharma Limited , a pharmaceutical company listed on the BSE (Scrip Code: 542934), has released its unaudited financial results for the half year ended September 30, 2025. The company's Board of Directors approved these results during a meeting held on November 13, 2025.

Financial Highlights

Key Points

• The board meeting commenced at 5:00 PM and concluded at 7:30 PM at the company's registered office in Mumbai.
• The financial results were reviewed by A Y & Company, Chartered Accountants, who issued a limited review report.
• The review was conducted in accordance with the Standard on Review Engagements (SRE) 2410.

Insider Trading Regulations

In compliance with SEBI regulations and the company's code of conduct for prohibition of insider trading:

• The "Trading Window" for the company's shares will reopen 48 hours after the announcement of the financial statement.
• This applies to Directors, Key Managerial Personnel, Designated Employees, and Connected Persons as defined in the company's insider trading code.

Auditor's Statement

A Y & Company, the company's auditors, stated in their review report:

"Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone financial results... contains any material misstatement."

The financial results and the limited review report have been submitted to the BSE Limited in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors and stakeholders are advised to consider these results in the context of the overall market conditions and the pharmaceutical sector's performance.